Ovid

OVID NASDAQ
2.350
-0.090
-3.69%
Closed 16:00 07/19 EDT
Open
2.480
Prev Close
2.440
High
2.497
Low
2.350
Volume
108.19K
Avg Vol (3M)
599.08K
52 Week High
11.02
52 Week Low
1.530
% Turnover
0.28%
Market Cap
90.93M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Ovid OVID stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
MORE >

Recently

Name
Price
%Change